Shimadzu Corp.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant decline in stock performance recently, contrasting with the broader market trends. Despite strong management efficiency and a premium valuation, the company reported a decrease in profits over the past year, alongside notable stock underperformance.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant stock decline on March 3, 2026. The company has underperformed compared to the Japan Nikkei 225 index, with notable decreases over the past week and month. Despite challenges, it maintains strong management efficiency and a low debt profile.

Shimadzu Corp. faced a decline on November 6, 2025, contrasting with the broader market's performance. The company has seen a year-to-date drop, despite maintaining strong management efficiency and low debt levels. Its stock valuation remains elevated compared to historical averages, prompting close observation from stakeholders.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw its stock decline significantly on October 29, 2025. Despite a challenging trading session, the company maintains strong management efficiency with a return on equity of 10.69% and a low debt profile, although its stock valuation remains elevated.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw its stock rise significantly on October 22, 2025. Despite recent gains, the company has struggled over the past year, with a notable decline, contrasting with the broader market's performance. Its market capitalization stands at JPY 1,075,623 million.

Shimadzu Corp. saw a significant decline in its stock price on October 14, 2025, contrasting with the Japan Nikkei 225's performance. Over the past week and year, the company has struggled, underperforming the index. Despite this, Shimadzu exhibits strong management efficiency and low debt levels, though its valuation remains high.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a notable rise on October 6, 2025, outperforming the Japan Nikkei 225. Despite recent gains, the company faces longer-term challenges with a year-to-date decline. It maintains strong management efficiency and low debt levels, ensuring financial stability.